Molecular Biomarkers In Cardiology

Molecular Biomarkers In Cardiology

Author: Pietro Scicchitano

Publisher: MDPI

Published: 2021-04-28

Total Pages: 276

ISBN-13: 3036508406

DOWNLOAD EBOOK

ear Colleagues, The approach to diseases is facing novel frontiers: targeting gene and improving person-centered medicine able to easily and specifically detect early stages of pathologies. The present book includes the most futuristic approaches to the identification of cardiac diseases by means of the most recent discoveries in molecular and genetic diagnosis. The articles will give you the opportunity to think of cardiac diseases as adverse conditions which can be more easily detected by means of technologies and the research spirit of us, physicians dedicated to humans’ care. Please enjoy this reading.


Novel Biomarkers for Heart Disease

Novel Biomarkers for Heart Disease

Author: Michael Lichtenauer

Publisher: MDPI

Published: 2020-12-28

Total Pages: 420

ISBN-13: 3039438832

DOWNLOAD EBOOK

Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.


Cardiac Markers, An Issue of Clinics in Laboratory Medicine

Cardiac Markers, An Issue of Clinics in Laboratory Medicine

Author: Kent Balanis Lewandrowski

Publisher: Elsevier Health Sciences

Published: 2014-03-28

Total Pages: 209

ISBN-13: 0323287115

DOWNLOAD EBOOK

Topics in this clinically focused publication devoted to Cardiac Markers include: Overview of cardiac markers in heart disease; Methodologies for measurement of cardiac markers; Natriuretic peptides in HF and ACS; Tropoinins and high sensitivity troponins; Point-of-care testing for cardiac markers; ST-2 and galectin 3 in patients with heart failure; Cardiac markers following heart surgery and percutaneous coronary intervention; Cholesterol, lipoproteins, high sensitivity CRP and other risk factors for atherosclerosis; Myocarditis and cardiac transplant and rejection; New molecular genetic tests in the diagnosis of heart disease; Biomarkers for cholesterol balance.


Biomarkers in Cardiovascular Disease

Biomarkers in Cardiovascular Disease

Author: Vijay Nambi

Publisher: Elsevier Health Sciences

Published: 2018-11-27

Total Pages: 400

ISBN-13: 0323548369

DOWNLOAD EBOOK

Get a quick, expert overview of the ways in which biomarkers can be used to assess and guide the management of cardiovascular disease in the clinical setting. This concise, clinically-focused resource by Dr. Vijay Nambi consolidates today’s available information on this rapidly changing topic into one convenient resource, making it an ideal, easy-to-digest reference for cardiology practitioners, fellows, and residents. Covers lab standards and statistical interpretation of biomarkers with a clinical focus. Discusses relevant conditions such as hypertension and diabetes as key markers of injury and prognosis. Includes current information on biomarkers to assess and guide the management of heart failure, acute coronary syndrome, chest pain, shortness of breath, and more. Concludes the book with a timely chapter on how biomarkers may guide cardiologists in the future.


Molecular biomarkers of cardiometabolic disease

Molecular biomarkers of cardiometabolic disease

Author: Mirjana Macvanin

Publisher: Frontiers Media SA

Published: 2024-08-22

Total Pages: 100

ISBN-13: 2832553494

DOWNLOAD EBOOK

Cardiometabolic disease (CMD) represents the major cause of mortality, accounting for one-third of all global deaths, 75% of which occur in middle- and low-income countries. CMD encompasses a broad spectrum of conditions characterized by limited prediction, based mainly on classical risk factors due to a lack of accurate molecular CMD predictors. Thus, there is an urgent need for improved diagnostics solutions to support early intervention and improve outcomes. Early detection and adequate intervention are crucial to prevent CMD-associated complications, encouraging the quest for appropriate biomarkers with diverse applications ranging from risk assessment and screening to diagnosis and prognosis. Different circulating biomarkers for quantifying the CMD risk have been reported in the literature, such as C-reactive protein (CRP), leptin, and adiponectin. In addition, accumulating evidence in the literature points to the emergence of novel CMD biomarkers, such as cytokines, various metabolites, apelin, microRNAs, inflammasome molecules, and cardiac fibrosis markers. However, large meta-analyses have not sufficiently investigated and confirmed their biological roles in CMD diagnosis, prognosis, and/or potential reduction.


Cardiovascular Biomarkers

Cardiovascular Biomarkers

Author: David A. Morrow

Publisher: Springer Science & Business Media

Published: 2010-04-28

Total Pages: 612

ISBN-13: 1597450510

DOWNLOAD EBOOK

In the four pages committed to a discussion of myocardial infarction in the first edition of Harrison’s Principles of Internal Medicine, published in 1950, there was no mention of use of the laboratory for management of patients. Thirty years later, when the first edition of Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine was published, 2 out of the 1943 pages in the text contained a discussion of the laboratory examinations in acute myocardial infarction. Our knowledge base of the multitude of ways that physicians can and should use the clinical chemistry laboratory has expanded dramatically since these classic texts were published. The nomenclature has changed: terms such as “cardiac enzymes” have given way to “cardiac biomarkers. ” The number of assays has multiplied, and the operating characteristics of available assays are impr- ing at a gratifying but dizzying rate. We now use biomarkers to diagnose cardiovascular diseases and also to frame our treatment strategies. Thus, there is a clear need for a scholarly compilation of the state of the art of cardiac biomarkers. Dr. David Morrow has expertly edited an authoritative book that answers this need. The 34 chapters in Cardiovascular Biomarkers: Pathophysiology and Disease Mana- ment were written by a group of individuals who are internationally recognized thought leaders and experts in clinical and laboratory medicine.


Biomarkers in Cardiovascular Diseases

Biomarkers in Cardiovascular Diseases

Author: Dimitris Tousoulis

Publisher: CRC Press

Published: 2013-07-29

Total Pages: 452

ISBN-13: 1466587148

DOWNLOAD EBOOK

The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book.


Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2010-06-25

Total Pages: 335

ISBN-13: 0309157277

DOWNLOAD EBOOK

Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.


Novel Biomarkers for Heart Disease

Novel Biomarkers for Heart Disease

Author: Michael Lichtenauer

Publisher:

Published: 2020

Total Pages: 420

ISBN-13: 9783039438846

DOWNLOAD EBOOK

Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.